Reaxys is a platform-independent, web-based product, so it doesn't require any installation. If you wish to operate in a Java-free environment, you should ensure that either GGA Ketcher or Elemental are your default editors. If you wish to run any other structure editor, Java version 1.5 or higher is a prerequisite.
Customers can access the product at www.reaxys.com. Platform independency means that it runs on Windows and Apple operating systems. We support Internet Explorer (6 or higher), Firefox (3 or higher) and Safari (4 or higher). Technical requirements are available in the Technical Product Info section.
Please Contact Sales to set up a demonstration.
We offer Corporate/Campus-Wide Access licenses at a flat-rate on a yearly subscription basis. This includes user authentication via IP-recognition so no individual user credentials are needed. This also means there are no seat-based delays or budgetary concerns about task-based searches.
Since Reaxys is web-based, remote access from outside your institution is also possible.
Reaxys currently supports Shibboleth but not ATHENS.
Yes. The full-text links in Reaxys gives direct access to the publisher home pages, including ScienceDirect, EspaceNet (the European Patent Office), and USPTO (the US Patent Office). Access to ScienceDirect and external publisher content requires a subscription license. EspaceNet and USPTO are publicly available.
Yes. Reaxys provides links to and from Scopus for all matching articles.
Elsevier has matched the compounds in Reaxys with three databases containing information about commercial availability: eMolecules, CambridgeSoft ACX and Accelrys ACD (Available Chemicals Directory).
In case of a successful match, icons are displayed beside the compound within the Reaxys interface. Simply click on the icon to access the corresponding service.
Please note: access to ACD and ACX data is provided through Accelrys and CambridgeSoft and requires separate licensing. All the relevant commercial information, including quantity, pricing and vendor information is available within the research workflow.
Security is one of our biggest concerns. Therefore, Reaxys is accessible using HTTPS protocol. This requires port 443 to be open in your institute’s firewall. Since this is a standard setting, it should not be a problem, unless the company prohibits all internet access.
Reaxys supports the following structure editors:
Dotmatics Elemental – default structure editor
Marvin Sketch (ChemAxon)
Symyx Draw (Accelrys)
ChemDraw Pro or higher (CambridgeSoft)
CrossFire Structure Editor (Elsevier)
Please note: if you wish to use structure editors other than Elemental, Marvin Sketch, or GGA Ketcher, a Reaxys plug-in has to be installed (download here). Please refer to Reaxys Help for more information on this topic.
Reaxys was designed to accommodate a number of industry standard structure editors. We will support the CrossFire Structure Editor until it is discontinued, but we will not be further developing or maintaining it. Therefore, we recommend that you switch to one of the many other available editors.
If you wish to use the CrossFire Structure Editor until it is discontinued, you or your information specialist must leave CrossFire Commander installed. If you have specific questions or preferences for structure editor features please don't hesitate to contact us at firstname.lastname@example.org .
Yes. Please Contact Us for more information.
Reaxys has this functionality. To allow the user to change the application settings, save queries and search history and set up alerts, a username and password must be set using the “Register” function. Login queries can then be loaded and saved locally on the workstation and results can be saved.
Technical product info
Reaxys/Reaxys Medicinal Chemistry is a unique web-based chemistry database consisting of deeply excerpted compounds and related factual properties, reaction and synthesis information as well as bibliographic data, navigated and displayed via an actionable interface.
Counts of the various types of content in the database can be found here: About Reaxys
|Windows PC||Macintosh PC|
Please note: with Microsoft ceasing the support of Windows XP Reaxys is not test on this platform any longer.
|Mac OS X 10.4 or higher|
|Internet Browser Software|
Please note: We cease the support of Microsoft Internet Explorer 6.x and Mozilla FireFox 3.x with the next Reaxys release in 2014. While we expect Reaxys to run with those browsers, certain features may not be supported.|
Microsoft Internet Explorer 7
Microsoft Internet Explorer 8 (with Java 1.6.0_11 or higher)
Microsoft Internet Explorer 9-11
Mozilla Firefox 3 to 3.5
Mozilla Firefox 3.6 (with Java 1.6.0_11 or higher)
Mozilla Firefox 4 or higher
Google Chrome 10 or higher
Please note: We cease the support of Mozilla FireFox 3.x with the next Reaxys release in 2014. While we expect Reaxys to run with those browsers, certain features may not be supported.|
Safari 4.0 or higher (Safari 3 is no longer being tested)
Mozilla Firefox 3.x
Mozilla Firefox 4 or higher
Google Chrome 10 or higher
|Java Runtime Environment (JRE)|
Sun Microsystems Java Version 5.0 or later also known as Java Runtime Environment (JRE) Version 1.5.0 (with external editors (see below) Java 4 is also supported).|
Note1: Java security settings must be changed from "High" to "Medium" for the Java version 1.7.0_45 in order to transfer drawn structure from java-required sturcture editors(MarvinSketch, Accelrys/ISISDraw, ChemDraw) to Reaxys. This is not required with Java version 1.7.0_51 and above.
Note 2: Reaxys was tested with the latest Java versions 1.6 and our QA team found some severe issues with the update 10 of this Java version.Therefore we do not recommend using Java 1.6.0_10. Please update to a later version of Java, e.g. build 13 or higher, where the Java issues have been fixed by Sun.
Note 3: Java needs to be enabled in the browser.
Recommendation: you may use the following website provided by SUN to check whether Java is correctly installed or not.
Apple Java Runtime Environment (JRE) 5.0 or higher|
Note 1: This website provides an overview on available Java versions for different Mac OS X 10 environments. In case of any issues regarding Java on a Macintosh please either contact our customer care team.
We also recommend to checkout the information on Apple's webpage.
|Supported Structure Editors|
- Elemental (Dotmatics; embedded editor)
- Ketcher (GGA; embedded editor)
Editors requiring Java:
Important note: please change the security settings for Java version 1.7.0_45 for the editor to work properly (see above)
- MarvinSketch (ChemAxon; embedded editor)
- ISIS/Draw (Accelrys; up to version 2.5)
- Accelrys/Symyx Draw (Accelrys; up to version 4.1)
- CrossFire Structure Editor (Elsevier; up to version 7)
- ChemDraw Pro 12 (CambridgeSoft; please note: the connector to Reaxys has been developed and is being maintained by CambridgeSoft. Please contact CambridgeSoft support in case of any issues.)
- ICEdit (InfoChem; please note: the connector to Reaxys has been developed and is being maintained by InfoChem. Please contact InfoChem support in case of any issues.)
Note 1: If other editors than MarvinSketch, Elemental or Ketcher are used, a plug-in has to be installed, which can be downloaded here.
After downloading the archive simply start one of the installers and follow the instructions.
(Dotmatics; see also left colum)|
- MarvinSketch (ChemAxon; see also left column)
- ChemDraw 12 on Mac OS 10.5 or higher (CambridgeSoft; please note ChemDraw Std and BioDraw Ultra are not supported)
|The Reaxys output feature supports the export of Reaxys data into Microsoft Word and Microsoft Excel formats. Please note that the created files requires Microsoft Word, Excel or Office Version 2003 or higher.|
Support Log In
Existing Customer? Log into the Reaxys product site and click on Help in the top menu.
Case Studies & Interviews
Dr. Peter Witte, Research Chemist at BASF (PDF, 855kb)
Ernie Cote, CEO of Chemical Information Services (PDF, 793kb)
Dr. John Parks, director of R&D Fine Chemistry at Albemarle Corporation (PDF, 580kb)
Dr. Jan Haller, a project manager in the Chemical Development Group at Novasep (PDF, 1,92mb)
Dr. Fabio Tucci, co-founder and COO of Epigen Biosciences (PDF, 1.2mb)
Dr. Gary Allred, co-founder, president and CEO of Synthonix (PDF, 670kb)
Dr. Bel Mekonnen is the CEO of the start-up drug discovery organization Hager Biosciences (PDF, 450kb)
Dr. Tommi Meulemans, project manager in Merachem's Organic Synthesis group (PDF, 719kb)
Takahashi Nakai, a medicinal chemist at Ironwood Pharmaceuticals (PDF, 696kb)
Education & Research
Professor Keiji Hirose, Associate Professor at Osaka University (PDF, 600kb)
Professor Forest Robertson of Western Connecticut State University (PDF, 750kb)
Professor Fabrizio Fabris of the University of Venice (PDF, 740kb)
Dr. Maikel Wijtmans of the VU University Amsterdam (PDF, 2mb)
Get more industry thought-leadership and insights.